Article
Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.
Clinical pharmacology and therapeutics - 1 Mar 2017
Elraiyah T, Jerde C R, Shrestha S, Wu R, Nie Q, Giama N H, Sarangi V, Roberts L R, Offer S M, Diasio R B
Abstract excerpt
Clinical studies have identified specific genetic variants in dihydropyrimidine dehydrogenase (DPD; DPYD gene) as predictors of severe adverse toxicity to the commonly used chemotherapeutic 5-fluorouracil (5-FU); however, these studies have focused on European and European-American populations. Our laboratory recently demonstrated that additional variants in non-European haplotypes are predictive of 5-FU...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.